Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial Receive the the latest news, research, and presentations from major ...
Hosted on MSN21d
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageTo position istaroxime for Phase 3 readiness, WINT is also enrolling a small Phase 2 study in SCAI Stage C, administering istaroxime to patients with the more severe form of cardiac shock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback